Streetbeat News

INDP

Indaptus Therapeutics, Inc.

Industry

Biotechnology

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Indaptus Therapeutics has successfully advanced its Phase 1 trial for Decoy20, a novel immuno-oncology therapy targeting advanced solid tumors. The trial confirmed the 'Pulse-Prime' hypothesis and identified a tolerable single dose for multi-dosing, which will be presented at ASCO.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:16 pm

Indaptus Therapeutics reported Q1 EPS of $(0.45), missing the consensus estimate of $(0.44) by 2.27%. This represents an 11.76% improvement over last year's Q1 losses of $(0.51) per share.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:26 pm

In Thursday's after-market session, health care stocks saw significant movements. Twist Bioscience, Jaguar Health, Tandem Diabetes Care, Indaptus Therapeutics, Ardelyx, and NKGen Biotech were among the gainers, with notable increases in their stock prices following earnings reports. Conversely, Cue Biopharma, Cardiff Oncology, Orchestra BioMed Holdings, Aptevo Therapeutics, Allarity Therapeutics, and Varex Imaging experienced declines.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 8:31 pm

In Wednesday's after-market session, health care stocks saw significant movements. Pulmonx, Butterfly Network, Compass Therapeutics, Sharps Technology, Blueprint Medicines, and Asensus Surgical were among the gainers, with Pulmonx leading at a 29.5% increase following their Q1 earnings release. Conversely, Envista Holdings, Accuray, Allakos, Psyence Biomedical, Schrodinger, and Indaptus Therapeutics experienced declines, with Envista Holdings dropping 12.5% after their Q1 earnings announcement.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 8:31 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Indaptus Therapeutics (NASDAQ:INDP) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 10:08 am

Indaptus Therapeutics revealed details about its Decoy Platform's mechanism of action at the AACR Research Annual Meeting, showing it activates multiple immune cell types for anti-tumor responses.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:35 am

In Friday's pre-market session, health care stocks showed significant movement. Protara Therapeutics led the gainers with a 40.3% increase, while Aesthetic Medical Intl experienced the largest drop among the losers, declining by 17.8%. Other notable movers include Candel Therapeutics and Etao International with substantial gains, and TC BioPharm and Imunon among the losers.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 12:09 pm

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced that it will present new data on its Decoy platform at the AACR Annual Meeting, demonstrating the platform's ability to activate multiple immune cell types for anti-tumor responses. The data, supporting the efficacy of Decoy10 and Decoy20 for cancer treatment, will be detailed in a poster session by Dr. Michael Newman. The findings are significant for advancing the treatment of solid tumors with the Decoy platform.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 12:41 pm

Indaptus Therapeutics (NASDAQ:INDP) reported Q4 earnings, beating estimates with an EPS of $-0.46 against an expected $-0.54. However, revenue remained unchanged from the previous year. Despite beating last quarter's EPS estimates, the share price dropped by 10% the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:40 pm

Indaptus Therapeutics reported a FY EPS of $(1.83), surpassing the $(1.95) estimate. Despite a 5.78% increase in losses from the previous year, its $13.4M cash balance is expected to sustain operations through Q3 of 2024.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:39 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.